Developer docs
API playgroundTry for free, no card

Search company profiles

Dilafor

Full company profile

uuid0002qh9

Namestring
Dilafor
Legal namestring
Dilafor AB
Websiteurl
dilafor.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Dilafor AB is a privately held Swedish drug development company founded in 2003 and headquartered at the Karolinska Institutet Science Park in Solna, Sweden. It is a single-asset, late-stage clinical company developing tafoxiparin, a proprietary heparan sulfate mimetic designed to initiate cervical ripening and myometrial remodeling to enable spontaneous onset of labor in term pregnant women, particularly first-time mothers planned for labor induction. The product is administered subcutaneously (with a planned daily autoinjector for home use) and has been evaluated in clinical studies on more than 650 pregnant women, with Phase IIb data showing 59% spontaneous onset or ripe cervix versus 39% on placebo and statistically significant cervical ripening (p<0.009). Preclinical data indicate tafoxiparin does not cross the placenta.

Dilafor does not sell a commercial product. Its business model is asset-light and licensing-driven: it captures upfront payments, development and sales milestones, and royalties from regional pharmaceutical partners who fund and execute late-stage clinical development and commercialization. The January 2026 binding term sheet with Exeltis (part of Insud Pharma) grants an exclusive semi-global license excluding China and Japan, with Exeltis funding pivotal Phase 3 trials and commercialization in exchange for milestones and stepped royalties up to double-digits. Lee's Pharmaceutical holds the China/Hong Kong/Macau/Taiwan rights (since 2014), and Opocrin S.p.A. is the commercial manufacturing partner for Europe, the US, CIS and Japan and also an equity holder. The company is owned primarily by KDev Investments AB (jointly held by KDventures AB, formerly Karolinska Development, and Rosetta Capital), alongside Östersjöstiftelsen and Praktikerinvest PE AB.

The asset is supported by substance and method-of-use patent protection, including a US patent granted October 2025 extending exclusivity for priming of labor until at least May 2043, alongside completed regulatory alignment with the FDA and European authorities (including a December 2024 SNSA with five EU national agencies) on Phase 3 study design. With no approved product, revenue is limited to licensing milestones; the addressable market is large, with US market analyses indicating a drug that induces cervical ripening could exceed USD 1 billion in annual US sales, and 30–50% of term pregnant women globally experiencing planned labor initiation.

Short descriptiontext

Dilafor AB is a Swedish, privately held drug development company developing tafoxiparin, a proprietary heparan sulfate mimetic in Phase 3 development for priming of labor in term pregnant women, monetizing through regional licensing partnerships (Exeltis, Lee's Pharmaceutical) and Opocrin manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
obstetric drug development, labor priming therapy, heparan sulfate mimetic, pharmaceutical licensing, cervical ripening drug
Industry1 code
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Obstetric Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Royalty Revenue
TypeLicensing Royalties
Description

Dilafor generates revenue through licensing agreements with pharmaceutical partners. The Exeltis agreement includes upfront payments, development-based milestones, sales-based milestone payments, and up to double-digit royalties on net sales. The Lee's Pharmaceutical agreement includes upfront payments, development and sales milestones, plus royalties on sales in licensed territories.

dilafor.com
2Milestone Payments
TypeLicensing Royalties
Description

Revenue from development and commercial milestone payments tied to clinical progress, regulatory approvals, and sales performance under partnership agreements.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Dilafor AB develops tafoxiparin, a proprietary heparan sulfate mimetic drug candidate designed for priming of labor in term pregnant women. The drug is administered as a daily subcutaneous injection or autoinjector to facilitate cervical ripening and myometrial remodeling, enabling spontaneous onset of labor. The company has completed Phase IIb clinical trials on more than 650 pregnant women and is preparing for Phase 3 trials following regulatory alignment with the FDA and European authorities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 59% of tafoxiparin-treated women experienced spontaneous onset of labor or reached a ripe cervix compared to 39% in placebo group
+4 more records
Product overview1 text field

Dilafor is a pharmaceutical development company with a single lead product - tafoxiparin, a proprietary heparan sulfate mimetic. The company focuses exclusively on developing this drug candidate for obstetrical indications, specifically priming of labor. Tafoxiparin is the company's sole product in advanced clinical development (Phase 3 ready), designed to enable cervical ripening and myometrial remodeling for spontaneous labor onset in term pregnant women.

Product and service1 record
1Tafoxiparin
CategoryObstetric Pharmaceuticals
Description

Proprietary heparan sulfate mimetic drug candidate in late-stage clinical development (Phase 3 ready) for priming of labor. It is administered as a daily subcutaneous injection or autoinjector to term pregnant women (particularly first-time mothers with unripe cervix planned for labor induction) to facilitate cervical ripening and myometrial remodeling, enabling spontaneous onset of labor. Clinical studies on 650+ pregnant women showed 59% experienced spontaneous onset of labor or ripe cervix versus 39% placebo, with safety profile supporting potential home-based self-administration.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-21
Description

Dilafor signed a binding term sheet with Exeltis, a global Women's Health company and part of Insud Pharma, for an exclusive semi-global license (excluding China and Japan) to develop and commercialize tafoxiparin for priming of labor. Exeltis will fund pivotal clinical trials, development, and commercialization. The deal includes milestone payments primarily linked to commercial performance and stepped royalties increasing based on net sales, with potential for up to double-digit royalties.

2Liverpool University
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-04-17
Description

Research collaboration with Liverpool University to study the potential inhibitory effect of tafoxiparin on SARS-CoV-2. Researchers provided evidence that heparin binds to the spike protein on SARS-CoV-2, and non-coagulant heparan sulfate mimetics like tafoxiparin may exhibit similar qualities. Dilafor provided tafoxiparin, data, and in-house knowledge.

dilafor.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2014-10-08
Description

Commercial manufacturing and partnership agreement with Opocrin for manufacturing of the active ingredient tafoxiparin. Opocrin appointed as main commercial manufacturing partner for European, US, CIS, and Japanese markets. Opocrin also made an investment in Dilafor as part of the agreement.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2014-02-20
Description

License and partnership agreement granting Lee's Pharmaceutical rights to manufacture, develop, and commercialize tafoxiparin for obstetrics and gynecological indications in China, Hong Kong, Macau, and Taiwan. Lee's will conduct and finance Phase II and Phase III trials in China. Dilafor receives upfront payment, development and sales milestones, plus royalties on sales.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company focused on women's health and reproductive medicine, including obstetric indications. Directly comparable as a small-cap, late-stage clinical developer addressing underserved areas of obstetrics with a similar licensing and partnership-driven business model.

TypeBroad incumbent
Description

Large privately-held reproductive health and obstetrics company that markets Cervidil (dinoprostone) and other labor induction products. Directly comparable as a key player in the labor induction space whose established products represent the standard-of-care Dilafor's tafoxiparin aims to disrupt.

TypeBroad incumbent
Description

Women's health-focused pharmaceutical company commercializing products across contraception, hormone therapy, and obstetrics. Comparable as a publicly-traded, women's health-focused pharma peer whose specialty commercial model and target prescribers overlap with Dilafor's obstetric market.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company focused on women's health with multiple late-stage programs. Comparable as a small, women-focused clinical developer pursuing underserved obstetric and gynecologic indications with similar licensing and partnership GTM.

TypeBroad incumbent
Description

Global women's health company spun out from Merck, with established franchises in contraception, fertility, and obstetrics. Comparable as a broad incumbent women's health company whose commercial footprint and physician relationships represent the channel Dilafor's eventual launch would target.

TypeEmerging player
Description

Women's health commercial-stage company focused on reproductive health products including hormone-free contraception. Comparable as a smaller, publicly-traded women's health specialist competing in overlapping OB/GYN prescribing channels with novel, underserved-mechanism products.

TypeBroad incumbent
Description

Women's health-focused pharmaceutical company (now part of Covis) with obstetric products such as Makena. Comparable as a women's health specialty player with established commercial infrastructure in obstetrics that competes for the same physician audience as a future tafoxiparin launch.

TypeBroad incumbent
Description

Diversified women's health company with significant presence in diagnostics, surgical, and obstetric markets. Comparable as a broad women's health incumbent whose existing OB/GYN commercial relationships and customer overlap make it a relevant strategic benchmark.

TypeBroad incumbent
Description

Major women's health and fertility medical device and pharmaceutical company, including products in assisted reproduction and obstetrics. Comparable as a broad incumbent serving the same maternal-fetal health customer base that tafoxiparin would target.

TypeOthers
Description

Spanish multinational pharmaceutical group operating in 40+ countries; parent of Exeltis, Dilafor's semi-global licensee for tafoxiparin. Included as an ecosystem participant and the commercial vehicle through which Dilafor would realize non-Asia ex-Japan royalties.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dilafor

Obstetric Pharmaceuticalsdilafor.com

Dilafor AB is a Swedish, privately held drug development company developing tafoxiparin, a proprietary heparan sulfate mimetic in Phase 3 development for priming of labor in term pregnant women, monetizing through regional licensing partnerships (Exeltis, Lee's Pharmaceutical) and Opocrin manufacturing.

What Dilafor does

Dilafor AB is a privately held Swedish drug development company founded in 2003 and headquartered at the Karolinska Institutet Science Park in Solna, Sweden. It is a single-asset, late-stage clinical company developing tafoxiparin, a proprietary heparan sulfate mimetic designed to initiate cervical ripening and myometrial remodeling to enable spontaneous onset of labor in term pregnant women, particularly first-time mothers planned for labor induction. The product is administered subcutaneously (with a planned daily autoinjector for home use) and has been evaluated in clinical studies on more than 650 pregnant women, with Phase IIb data showing 59% spontaneous onset or ripe cervix versus 39% on placebo and statistically significant cervical ripening (p<0.009). Preclinical data indicate tafoxiparin does not cross the placenta.

Dilafor does not sell a commercial product. Its business model is asset-light and licensing-driven: it captures upfront payments, development and sales milestones, and royalties from regional pharmaceutical partners who fund and execute late-stage clinical development and commercialization. The January 2026 binding term sheet with Exeltis (part of Insud Pharma) grants an exclusive semi-global license excluding China and Japan, with Exeltis funding pivotal Phase 3 trials and commercialization in exchange for milestones and stepped royalties up to double-digits. Lee's Pharmaceutical holds the China/Hong Kong/Macau/Taiwan rights (since 2014), and Opocrin S.p.A. is the commercial manufacturing partner for Europe, the US, CIS and Japan and also an equity holder. The company is owned primarily by KDev Investments AB (jointly held by KDventures AB, formerly Karolinska Development, and Rosetta Capital), alongside Östersjöstiftelsen and Praktikerinvest PE AB.

The asset is supported by substance and method-of-use patent protection, including a US patent granted October 2025 extending exclusivity for priming of labor until at least May 2043, alongside completed regulatory alignment with the FDA and European authorities (including a December 2024 SNSA with five EU national agencies) on Phase 3 study design. With no approved product, revenue is limited to licensing milestones; the addressable market is large, with US market analyses indicating a drug that induces cervical ripening could exceed USD 1 billion in annual US sales, and 30–50% of term pregnant women globally experiencing planned labor initiation.

Dilafor firmographics

Firmographics
Name
Dilafor
Legal name
Dilafor AB
Website
https://dilafor.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
1–10 employees
Short description
Dilafor AB is a Swedish, privately held drug development company developing tafoxiparin, a proprietary heparan sulfate mimetic in Phase 3 development for priming of labor in term pregnant women, monetizing through regional licensing partnerships (Exeltis, Lee's Pharmaceutical) and Opocrin manufacturing.
Ownership category
akta.pro rank

Dilafor industry classification

Industry
Product category
Obstetric Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Obstetric drug development
  • Labor priming therapy
  • Heparan sulfate mimetic
  • Pharmaceutical licensing
  • Cervical ripening drug

Where Dilafor is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Dilafor business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Licensing and Royalty Revenue: Dilafor generates revenue through licensing agreements with pharmaceutical partners. The Exeltis agreement includes upfront payments, development-based milestones, sales-based milestone payments, and up to double-digit royalties on net sales. The Lee's Pharmaceutical agreement includes upfront payments, development and sales milestones, plus royalties on sales in licensed territories.
  2. Milestone Payments: Revenue from development and commercial milestone payments tied to clinical progress, regulatory approvals, and sales performance under partnership agreements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Dilafor product offering

Product offering

Core offering

Dilafor AB develops tafoxiparin, a proprietary heparan sulfate mimetic drug candidate designed for priming of labor in term pregnant women. The drug is administered as a daily subcutaneous injection or autoinjector to facilitate cervical ripening and myometrial remodeling, enabling spontaneous onset of labor. The company has completed Phase IIb clinical trials on more than 650 pregnant women and is preparing for Phase 3 trials following regulatory alignment with the FDA and European authorities.

Product overview

Dilafor is a pharmaceutical development company with a single lead product - tafoxiparin, a proprietary heparan sulfate mimetic. The company focuses exclusively on developing this drug candidate for obstetrical indications, specifically priming of labor. Tafoxiparin is the company's sole product in advanced clinical development (Phase 3 ready), designed to enable cervical ripening and myometrial remodeling for spontaneous labor onset in term pregnant women.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tafoxiparin Proprietary heparan sulfate mimetic drug candidate in late-stage clinical development (Phase 3 ready) for priming of labor. It is administered as a daily subcutaneous injection or autoinjector to term pregnant women (particularly first-time mothers with unripe cervix planned for labor induction) to facilitate cervical ripening and myometrial remodeling, enabling spontaneous onset of labor. Clinical studies on 650+ pregnant women showed 59% experienced spontaneous onset of labor or ripe cervix versus 39% placebo, with safety profile supporting potential home-based self-administration.

Quantifiable outcome

  • 59% of tafoxiparin-treated women experienced spontaneous onset of labor or reached a ripe cervix compared to 39% in placebo group
  • +4 more outcomes

Companies that use Dilafor

Customer profile

Segments2 records

Ideal customer profiles2 records

Dilafor technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Dilafor partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • ExeltiscoreChannel Partner/ Reseller/ Distributor · 21 January 2026Dilafor signed a binding term sheet with Exeltis, a global Women's Health company and part of Insud Pharma, for an exclusive semi-global license (excluding China and Japan) to develop and commercialize tafoxiparin for priming of labor. Exeltis will fund pivotal clinical trials, development, and commercialization. The deal includes milestone payments primarily linked to commercial performance and stepped royalties increasing based on net sales, with potential for up to double-digit royalties.
  • Liverpool UniversityminorStrategic or Co-development Partner · 17 April 2020Research collaboration with Liverpool University to study the potential inhibitory effect of tafoxiparin on SARS-CoV-2. Researchers provided evidence that heparin binds to the spike protein on SARS-CoV-2, and non-coagulant heparan sulfate mimetics like tafoxiparin may exhibit similar qualities. Dilafor provided tafoxiparin, data, and in-house knowledge.
  • Opocrin S.p.AcoreOEM/ Whitelabel/ Licensing Partner · 8 October 2014Commercial manufacturing and partnership agreement with Opocrin for manufacturing of the active ingredient tafoxiparin. Opocrin appointed as main commercial manufacturing partner for European, US, CIS, and Japanese markets. Opocrin also made an investment in Dilafor as part of the agreement.
  • Lee's Pharmaceutical Holdings LtdcoreChannel Partner/ Reseller/ Distributor · 20 February 2014License and partnership agreement granting Lee's Pharmaceutical rights to manufacture, develop, and commercialize tafoxiparin for obstetrics and gynecological indications in China, Hong Kong, Macau, and Taiwan. Lee's will conduct and finance Phase II and Phase III trials in China. Dilafor receives upfront payment, development and sales milestones, plus royalties on sales.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Dilafor competitors and assessment

Company assessment

Direct peers

  • ObsEva SA: Clinical-stage biopharmaceutical company focused on women's health and reproductive medicine, including obstetric indications. Directly comparable as a small-cap, late-stage clinical developer addressing underserved areas of obstetrics with a similar licensing and partnership-driven business model.
  • Dare Bioscience: Clinical-stage biopharmaceutical company focused on women's health with multiple late-stage programs. Comparable as a small, women-focused clinical developer pursuing underserved obstetric and gynecologic indications with similar licensing and partnership GTM.

Broad incumbents

  • Ferring Pharmaceuticals: Large privately-held reproductive health and obstetrics company that markets Cervidil (dinoprostone) and other labor induction products. Directly comparable as a key player in the labor induction space whose established products represent the standard-of-care Dilafor's tafoxiparin aims to disrupt.
  • TherapeuticsMD: Women's health-focused pharmaceutical company commercializing products across contraception, hormone therapy, and obstetrics. Comparable as a publicly-traded, women's health-focused pharma peer whose specialty commercial model and target prescribers overlap with Dilafor's obstetric market.
  • Organon & Co. Global women's health company spun out from Merck, with established franchises in contraception, fertility, and obstetrics. Comparable as a broad incumbent women's health company whose commercial footprint and physician relationships represent the channel Dilafor's eventual launch would target.
  • AMAG Pharmaceuticals (Covis Pharma): Women's health-focused pharmaceutical company (now part of Covis) with obstetric products such as Makena. Comparable as a women's health specialty player with established commercial infrastructure in obstetrics that competes for the same physician audience as a future tafoxiparin launch.
  • Hologic: Diversified women's health company with significant presence in diagnostics, surgical, and obstetric markets. Comparable as a broad women's health incumbent whose existing OB/GYN commercial relationships and customer overlap make it a relevant strategic benchmark.
  • CooperSurgical: Major women's health and fertility medical device and pharmaceutical company, including products in assisted reproduction and obstetrics. Comparable as a broad incumbent serving the same maternal-fetal health customer base that tafoxiparin would target.

Emerging players

  • Evofem Biosciences: Women's health commercial-stage company focused on reproductive health products including hormone-free contraception. Comparable as a smaller, publicly-traded women's health specialist competing in overlapping OB/GYN prescribing channels with novel, underserved-mechanism products.

Others

  • Insud Pharma (Exeltis parent): Spanish multinational pharmaceutical group operating in 40+ countries; parent of Exeltis, Dilafor's semi-global licensee for tafoxiparin. Included as an ecosystem participant and the commercial vehicle through which Dilafor would realize non-Asia ex-Japan royalties.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

Dilafor social profiles

Digital presence

Dilafor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dilafor leadership team

Management profile

Number of profiles

Profiles14 records

Dilafor funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dilafor M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dilafor

What does Dilafor do?

Dilafor AB develops tafoxiparin, a proprietary heparan sulfate mimetic drug candidate designed for priming of labor in term pregnant women. The drug is administered as a daily subcutaneous injection or autoinjector to facilitate cervical ripening and myometrial remodeling, enabling spontaneous onset of labor. The company has completed Phase IIb clinical trials on more than 650 pregnant women and is preparing for Phase 3 trials following regulatory alignment with the FDA and European authorities.

Is Dilafor a public or private company?

Dilafor is a private company. It is classified as venture growth investor backed and is currently operating.

When was Dilafor founded?

Dilafor was founded in 2003. It employs 1 to 10 people.

Where is Dilafor based?

Dilafor is headquartered in Solna, Sweden, in the Europe region.

How does Dilafor make money?

Two revenue lines are on record. Licensing and Royalty Revenue is the primary driver. The others are milestone Payments.

Who are Dilafor's main competitors?

Direct peers on record are ObsEva SA and Dare Bioscience. Broad incumbents are Ferring Pharmaceuticals, TherapeuticsMD, Organon & Co., AMAG Pharmaceuticals (Covis Pharma), Hologic and CooperSurgical. Evofem Biosciences is listed as an emerging player. Insud Pharma (Exeltis parent) is listed as an others.

Does Dilafor have an API?

No public API is recorded for Dilafor.

What industry is Dilafor in?

Dilafor's product category is Obstetric Pharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireBokslutskommuniké för januari – december 2025KDventures AB (formerly Karolinska Development AB) published its year-end report for January-December 2025 on February 13, 2026, reporting a full-year loss of SEK -193.9 million compared to SEK -8.1 million in 2024. The company completed a rights issue raising approximately SEK 115.2 million before issuance costs, with 57% subscription rate, and changed its name from Karolinska Development AB to KDventures AB following shareholder approval on January 8, 2026. Multiple portfolio companies achieved key milestones including Dilafor securing a US patent and signing a licensing term sheet with Exeltis, AnaCardio reporting positive Phase 2a results for heart failure treatment, and SVF Vaccines entering a reverse acquisition agreement with Novakand Pharma valued at approximately SEK 55 million.GlobeNewswireKarolinska Development’s portfolio company Dilafor signs binding term sheet with Exeltis for a license agreement regarding tafoxiparinDilafor signed a binding term sheet with Exeltis for an exclusive semi-global license to tafoxiparin for priming of labor, excluding China and Japan. Exeltis will fund pivotal trials and commercialization, with milestone payments and royalties. The deal could shift labor induction from hospital to home use.GlobeNewswireKarolinska Development’s portfolio company Dilafor receives patent in the US for tafoxiparin in priming of laborDilafor received a US patent for tafoxiparin in labor priming, protecting the drug until at least May 2043. The patent supports Dilafor's advance into Phase 3 clinical trials, with the drug ready for that step. The patent may enable an at-home treatment option, reducing hospital-based induction costs.GlobeNewswireKarolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authoritiesDilafor completed regulatory meetings with the FDA and European Health Agencies on its labor priming drug candidate tafoxiparin, aligning on Phase 3 study design. The meetings, including a December 2024 SNSA, covered primary endpoints and inclusion criteria. Dilafor will now finalize planning for pivotal Phase 3 trials in the US and Europe.GlobeNewswireKarolinska Development’s portfolio company Dilafor reports maintained effect in the extension study of tafoxiparinDilafor's extended phase 2b study of tafoxiparin met its objective, showing cervical ripening effect persists in 164 women. A clear dose-response relationship was observed, reinforcing the drug's potential to reduce risks in planned start of labor.GlobeNewswireKarolinska Development’s portfolio company Dilafor has completed recruitment to an extension study of tafoxiparinDilafor, a portfolio company of Karolinska Development, enrolled the last patient in an extension study of its drug candidate tafoxiparin. The study includes 164 women and aims to document effects at further doses, with results expected in Q1 2023. The extension follows a positive phase 2b trial in June 2021.GlobeNewswireKarolinska Development’s portfolio company Dilafor recruits first patient to Phase 2a study of tafoxiparin in women diagnosed with preeclampsiaDilafor enrolled the first patient in a Phase 2a study of tafoxiparin for preeclampsia, with 23 pregnant women randomized to treatment or standard care. The study will assess safety, tolerability, and efficacy over up to 4 weeks. Preeclampsia affects 5-8% of pregnancies and remains a leading cause of maternal death.GlobeNewswireKarolinska Development increases book value of Dilafor that is indirectly owned via KDev Investments AB by SEK 450 millionKarolinska Development increased the book value of its holding in Dilafor by SEK 450 million, based on a risk-adjusted external valuation. The increase boosted Q2 2021 net result by about SEK 250 million, or SEK 1.42 per share. Dilafor's drug candidate tafoxiparin showed positive results in a phase 2b study on cervix ripening.GlobeNewswireKarolinska Development’s portfolio company Dilafor presents positive results from a phase 2b study of tafoxiparinDilafor concluded a phase 2b study of tafoxiparin, showing significant positive cervical ripening in first-time mothers. The study included 170 patients, with results statistically significant (p<0.009). Dilafor plans to prolong the study to test two lower doses.GlobeNewswireKarolinska Development’s portfolio company Dilafor completes patient inclusion to Phase 2b trial of its drug candidate tafoxiparinDilafor completed patient inclusion to its Phase 2b trial of tafoxiparin, a drug candidate to shorten labor induction time. The double-blind, placebo-controlled study enrolled 170 first-time mothers with immature cervix, with results expected before the end of the first half of 2021.